Ugandan Pharmaceutical Company to Invest $80 Million for Expansion; Some Funds Will Go to Generic AIDS, Malaria Drug Plants
February 2, 2011
"Quality Chemicals Industries Ltd., a Ugandan pharmaceuticals manufacturer partly owned by India's Cipla Ltd., said it plans to invest $80 million in two separate expansion programs over the next two years," Bloomberg Businessweek reports. According to the news service, $30 million of the funds will be used to expand the capacity of the company's generic AIDS and malaria-drug plants, and $50 million will be put towards "a new production line for pharmaceutical ingredients." Bloomberg notes that "Quality Chemicals' plant in [the Ugandan capital city] Kampala has the capacity to produce 6 million malaria or generic AIDS tablets daily, with room for expansion, according to the company." The piece notes the numbers of patients living with HIV/AIDS and malaria in Uganda as well as neighboring countries who could benefit from access to generic medications (Ojambo, 2/1).
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Global Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)